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Abstract 
The uptake of personal ECG devices is poised to 
explode in coming years. This review considers the 
potential impact of this on the cardiology department of an 
NHS teaching trust in the UK. The authors conclude that 
such devices may substantially increase the workload of a 
service already under significant pressure, with unclear 
benefit to patients. Potential solutions to this issue include 
novel algorithms (perhaps deep learning) to minimize false 
positive results. 
 
1. Introduction 
With the prevalence of personal ECG devices already 
on the rise and the Apple Watch Series 4 recently hitting 
the market, the number of daily ECG recordings in the 
developed world is poised to explode. [1] While some 
individuals will undoubtedly benefit from enhanced 
diagnosis of cardiac arrhythmias, the consequences of false 
alarms are likely to be detrimental to patients and clinicians 
alike. This article aims to describe the possible impact of 
this technology on a typical cardiology department of a UK 
National Health Service (NHS) trust. 
 
1.1. The clinical setting 
The NHS is the largest single-payer healthcare system, 
the fifth largest employer globally (after the US 
Department of Defense, the Chinese People’s Liberation 
Army, Wallmart and MacDonald’s) and is responsible for 
a population of approximately 66 million [2,3]. For this 
reason, it is often considered to be a particularly good test 
bed for emerging healthcare technologies. [4] 
The Southern Health and Social Care Trust (SHSCT) is 
an NHS trust in Northern Ireland. The population of the 
SHSCT’s catchment area is approximately 360,000, which 
has grown substantially over the last decade. [5] The 
Northern Irish population is ageing more rapidly, scores 
lower on socioeconomic metrics and has a lower average 
life expectancy than the rest of the UK. [6,7,8,9] Waiting 
times for outpatient consultations are correspondingly 
longer than the national average. [10]  
The cardiology department of the SHSCT runs a 
coronary care unit at each of two teaching hospitals, with 
six and eight beds respectively. There are an additional 25 
permanent inpatient cardiology beds at the larger of the 
two hospitals, along with two interventional cardiac 
catheterisation laboratories. The department records about 
55,000 inpatient episodes yearly and has a high volume of 
outpatient encounters (internal statistics). 
 
1.2. Current ambulatory ECG service 
At present, Holter monitors and cardiac event recorders 
can be requested directly by physicians outside the 
cardiology department, including general practitioners 
(GPs). Implantable loop recorders (ILRs) are only 
requested by members of the cardiology team and must be 
approved by a consultant prior to implantation. 
Recordings from wearable devices are automatically 
annotated by specialized software (Sentinel, Spacelabs 
Healthcare, Snoqualmie, WA, US) and reviewed by one of 
13 full time equivalent cardiac physiologists (CPs). 
Approximately 2,500 studies are undertaken and reported 
annually. According to SHSCT CPs, reporting a single 
study takes between 15 minutes and several hours. 
The responsibility for acting upon the report generated 
by a wearable ECG monitor lies with the requesting 
consultant. No study is undertaken without a responsible 
consultant physician designated on the request form. 
 
2. Personal ECG devices 
In their 2018 review, Banshal and Joshi identified 15 
widely available personal ECG devices, but only six that 
were associated with Pubmed-listed studies. [11] Three of 
these are currently intended for prescription by medical 
professionals and three are available to individual 
consumers online. Table 1 shows representative prices for 
the commercially available devices, with the addition of 
the Apple Series 4 Watch (not included in the 2018 review 
as it had not been released). 
This review will focus primarily on the impact of two 
devices: the AliveCor Mobile device and the Apple 
smartwatch. 
 
2.1. Characteristics of selected devices 
The AliveCor device is chosen as both the most 
affordable of the peer reviewed devices and the best 
supported by published evidence. It has been reviewed 
favourably by the National Institute for Clinical Excellence 
(NICE), who noted that the sensitivity and specificity for 
the automated detection of atrial fibrillation (AF) has been 
reported in multiple studies as above 85% and 90%, 
respectively. [12] 
The ECG-enabled Apple Series 4 Watch is chosen for 
having, by far, the highest predicted sales figures. In 2018, 
prior to the introduction of ECG capabilities, Apple is 
estimated to have shipped 22.5 million watches globally. 
[13] It is not clear how many of the Series 4 watches have 
been bought in the UK since it went on sale in September 
2018, nor how many owners use the ECG technology. 
However, the authors of this study consider these sales 
figures to be the most compelling reason to begin thinking 
about the logistics of the widespread use of self-prescribed 
ECG monitoring.  
Device  Cost Outlet 
Omron Heart Scan  £699.99 Amazon.co.uk 
AliveCor Mobile £99 AliveCor.com 
REKA Health N/A  
Zenicor ECG N/A  
Schiller MINISCOPE £1134 EKGshop.com 
ZioPatch N/A  
Apple Series 4 Watch £389 John Lewis 
Table 1. Representative costs of personal ECG devices. 
  According to a press release by Apple, the sensitivity and 
specificity for the automated detection of atrial fibrillation 
(AF) is 98.3% and 99.6%, respectively. [14] The study 
from which these figures were obtained has not yet been 
published in a peer reviewed journal. The authors consider 
that there is currently insufficient evidence to support a 
significant difference in device performance between the 
Apple Watch and the AliveCor device, and will assume 
parity henceforth. 
At present, both AliveCor and Apple aim to 
automatically diagnose normal sinus rhythm (NSR) and 
AF. Other classifications are tachycardia, bradycardia or 
inconclusive / unreadable. Diagnoses of such traces must 
be made manually. To this end, both devices can store ECG 
tracings in PDF format for transmission to the patient’s 
clinician.  
AliveCor offers US customers a free manual analysis of 
their first ECG trace by a cardiologist, and analysis of 
future recordings for a fee. 
ECG recordings are single-lead and must be user-
initiated on both devices. On the Apple Watch, users touch 
a finger to the digital crown of the watch. On the AliveCor 
device, users place a finger from each hand on the 
electrodes. Recordings on the Apple device last 30 
seconds. Recordings on the AliveCor device last 40 
seconds. [15,16] 
3. Pathway for abnormal recordings 
If either Apple or AliveCor applications detect rhythms 
other than NSR, both companies return responsibility to 
the user by suggesting they consult a physician. It is at the 
point where a UK user sends ECG data to a physician that 
problems may begin arise from a healthcare provider’s 
perspective. Within the NHS, self-referral to a specialist is 
only possible under exceptional circumstances (for 
example, one may see an ophthalmologist directly in eye 
casualty) or via a private clinic for a fee. In general, 
however, a patient’s first point of contact is their GP or an 
emergency department (ED) physician. For personal 
ECGs, it is likely be the former. 
At present, there appears to be significant variation in 
how comfortable GPs are with ECG interpretation. In the 
experience of the SHSCT cardiology department, some 
referrals from the community arrive with accurate 
interpretation of even relatively rare ECG abnormalities 
(e.g. “?Brugada”), whereas others include fundamental 
mistakes such as confusing sinus arrhythmia for AF due to 
irregular R-R intervals but in the presence of clear P waves.  
Regardless of individual competence, however, there 
can be little doubt that primary care is under unprecedented 
pressure and that GPs are unlikely to relish the prospect of 
an additional source of work. [17] It is anticipated by the 
authors, therefore, that most personal ECG recordings 
submitted to GPs will be referred to the cardiology 
department for review.  
 
3.1. Impact on cardiology services 
In the SHSCT, the current wait for a routine Holter 
monitor is around 52 weeks (internal statistic). However, 
all studies are currently ordered by a qualified clinician 
who, if they deem the test to be urgent, can stipulate a 
shorter time frame. In the absence of any clear way to 
triage personal recordings, it seems likely that ECGs 
mandated directly by patients will be considered a lower 
priority than studies ordered by qualified medical 
professionals. It is therefore likely that they will be 
associated with a substantial delay in reporting. This would 
Figure 1. An Apple Watch. The Series 4 model is ECG capable. 
put some patients at risk, particularly if they have declined 
to seek expert attention via established channels as a 
consequence of having submitted potentially diagnostic 
information. 
Furthermore, if the uptake of personal ECG monitoring 
among SHSCT patients is significant, the extra workload 
could cause delays across the CP service. This includes all 
ambulatory ECG monitoring, pacemaker checks, exercise 
stress testing, echocardiography services and all cath lab 
sessions. 
Let it be assumed that, two years from now, the entire 
Apple smartwatch range is ECG capable and continues to 
sell at 22.5 million units per year. If we disregard a likely 
preponderance of sales towards industrialised nations like 
the UK and instead assume an even global sales 
distribution among 7 billion people, approximately 1000 
watches would be acquired by the SHSCT population. 
Selder et al. (2019) found that patients using the 
AliveCor Kardia Mobile device submitted a median of 28 
ECGs per patient per year, though this was among patients 
presenting to cardiology services with palpitations and is 
likely to be higher than a non-selected population. [18] 
Indeed, 19% of ECGs submitted showed AF, whereas AF 
prevalence among under 65s in the general population (the 
demographic into which the majority of Apple Watch 
owners fall) is around 2%. [19,20] 
Nonetheless, 20% of all ECGs submitted were flagged 
as potentially abnormal by the device software and 
subsequently found to either show NSR or be 
unclassifiable. A press release from Stanford University 
regarding the Apple Heart Study noted that a little over half 
of users receiving an abnormal pulse warning sought 
medical attention. [21] If there was a similar false positive 
rate among Apple Watch owners, and if 50% decided to 
seek medical review of these recordings, this could result 
in 2,800 additional ECGs being analysed by SHSCT staff 
per year: a 100% increase in outpatient studies analysed. 
 
3.2. Benefit to patients 
Halcox et al. (2017) report AF diagnosis rates among 
over 65s undergoing routine care (RC) vs twice-weekly 
ECG monitoring with the AliveCor device. 5 patients 
receiving RC were diagnosed with AF over the course of a 
year, compared with 19 in the AliveCor group (hazard ratio 
3.9, p=0.007). [22] They were unable to demonstrate a 
statistically significant difference in rates of 
cerebrovascular events over the 12-month study, but 
Boriani et al. (2014) previously concluded that silent AF is 
associated with a modifiable risk of embolic stroke if 
anticoagulants are appropriately prescribed. [23] Though 
the duration of AF warranting anticoagulation remains a 
matter of debate, it seems reasonable to conclude that 
higher rates of AF and appropriate anticoagulant 
prescription may be associated with lower rates of embolic 
stroke. 
However, the authors note that the population 
prevalence of AF among Halcox’s over 65 subjects is 9%, 
compared with 2% among most Apple Watch owners. [20] 
Furthermore, the rate of embolic stroke among otherwise 
well, young patients diagnosed with AF on routine 
screening is unknown (Boriani studied patients with pre-
existing cardiac conditions). There is, therefore, 
insufficient data to estimate the cost per quality adjusted 
life year (QALY) of personal ECG monitoring, nor to 
quantify the impact of high false positive rates on the wider 
cardiology service and the psychological wellbeing of 
patients. The authors feel that it is not clear that the 
widespread uptake of personal ECG devices will benefit 
patients in the SHSCT. 
4. A technological solution to a 
technological problem? 
As a final note, recent developments in deep learning-
based arrhythmia detection may prove timely in light of the 
issues discussed in this review. Hannun et al. (2019) claim 
to have achieved “cardiologist-level” using a 34-layer 
convolutional neural network trained on large scale 
ambulatory ECG data. [24] This is a relatively nascent 
technology but if the results reported in this paper are 
reproducible by other groups, this may substantially reduce 
the number of false positive results and shift the risk-
benefit balance in favour of personal ECG devices.  
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